| Name | Title | Contact Details |
|---|
KishHealth System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. KishHealth System is based in Dekalb, IL. You can find more information on KishHealth System at www.kishhealth.org
AlloSource is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Centennial, CO. To find more information about AlloSource, please visit www.allosource.org
Natural Health Trends Corp. is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UConn Health is a vibrant, integrated academic medical center that is entering an era of unprecedented growth in all three areas of its mission: academics, research, and clinical care. UConn Health is at the center of Bioscience Connecticut, a bold plan introduced by Connecticut Governor Dannel P. Malloy and approved by the Connecticut General Assembly in 2011. The plan will strengthen Connecticut`s position as a national and global leader for bioscience innovation and improve access to quality health care for Connecticut citizens for generations to come. Based in Farmington, Connecticut – a popular suburb of the state`s capitol of Hartford – UConn Health is home to the School of Medicine, School of Dental Medicine, John Dempsey Hospital, UConn Medical Group, UConn Health Partners, University Dentists and a thriving research enterprise. With approximately 5,000 employees, UConn Health is a major economic driver in the region, generating nearly $1 billion annually in gross state product. It is closely linked with the University of Connecticut`s main campus in Storrs through multiple, cross-campus academic projects.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.